[1]
|
Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., Coresh, J., Culleton, B., Lee Hamm, L., et al. (2003) Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preven-tion. Circulation, 108, 2154-2169. https://doi.org/10.1161/01.CIR.0000095676.90936.80
|
[2]
|
Liyanage, T., Nino-miya, T., Jha, V., Neal, B., Patrice, H.M., Okpechi, I., et al. (2015) Worldwide Access to Treatment for End-Stage Kid-ney Disease: A Systematic Review. Lancet, 385, 1975-1982.
https://doi.org/10.1016/S0140-6736(14)61601-9
|
[3]
|
Vanholder, R., De Smet, R., Glorieux, G., Argilés, A., Baurmeister, U., Brunet, P., et al. (2003) Review on Uremic Toxins: Classification, Concentration, and Interindividual Variability. Kidney International, 63, 1934-1943.
https://doi.org/10.1046/j.1523-1755.2003.00924.x
|
[4]
|
Wang, Z., Luo, Y., Yang, S., et al. (2021) Premature Deaths Caused by Smoking in Sichuan, Southwest China, 2015-2030. Scientific Reports, 11, Article No. 171. https://doi.org/10.1038/s41598-020-79606-2
|
[5]
|
Zhang, L., Wang, F., Wang, L., Wang, W., Liu, B., Liu, J., et al. (2012) Prevalence of Chronic Kidney Disease in China: A Cross-Sectional Survey. Lancet, 379, 815-822. https://doi.org/10.1016/S0140-6736(12)60033-6
|
[6]
|
Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., O’Callaghan, C.A., Lasserson, D.S., et al. (2016) Global Prevalence of Chronic Kidney Disease—A Systematic Review and Me-ta-Analysis. PLoS ONE, 11, Article ID: e0158765.
https://doi.org/10.1371/journal.pone.0158765
|
[7]
|
Burgess, E., Muirhead, N., Rene de Cotret, P., Chiu, A., Pichette, V., Tobe, S., et al. (2009) SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal Dose of Candesartan in Proteinuric Renal Disease. Journal of the American Society of Nephrology, 20, 893-900. https://doi.org/10.1681/ASN.2008040416
|
[8]
|
Shabaka, A., Cases-Corona, C. and Fernandez-Juarez, G. (2021) Therapeutic Insights in Chronic Kidney Disease Progression. Frontiers in Medicine, 8, Article ID: 645187. https://doi.org/10.3389/fmed.2021.645187
|
[9]
|
Fernandez Juarez, G., Luño, J., Barrio, V., et al. (2013) Effect of Dual Blockade of the Renin-Angiotensin System on the Progression of Type 2 Diabetic Nephropathy: A Randomized Trial. American Journal of Kidney Diseases, 61, 211-218. https://doi.org/10.1053/j.ajkd.2012.07.011
|
[10]
|
Cosimato, C., Agoritsas, T. and Mavrakanas, T.A. (2021) Miner-alocorticoid Receptor Antagonists in Patients with Chronic Kidney Disease. Pharmacology & Therapeutics, 219, Article ID: 107701.
https://doi.org/10.1016/j.pharmthera.2020.107701
|
[11]
|
Teasdale, E.J., Leydon, G., Fraser, S., et al. (2017) Patients’ Experiences After CKD Diagnosis: A Meta-ethnographic Study and Systematic Review. American Journal of Kidney Diseases, 70, 656-665.
https://doi.org/10.1053/j.ajkd.2017.05.019
|
[12]
|
Perkovic, V., Jardine, M.J., Neal, B., et al. (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine, 380, 2295-2306. https://doi.org/10.1056/NEJMoa1811744
|
[13]
|
Milder, T.Y., Stocker, S.L., Samocha-Bonet, D., et al. (2019) So-dium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes-Cardiovascular and Renal Benefits in Patients with Chronic Kidney Disease. European Journal of Clinical Pharmacology, 75, 1481-1490. https://doi.org/10.1007/s00228-019-02732-y
|
[14]
|
Spithoven, E.M., Kramer, A., Meijer, E., Orskov, B., Wanner, C., Abad, J.M., et al. (2014) Renal Replacement Therapy for Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Europe: Prevalence and Survival—An Analysis of Data from the ERA-EDTA Registry. Nephrology Dialysis Trans-plantation, 29, 15-25.
https://doi.org/10.1093/ndt/gfu017
|
[15]
|
Wu, T.C., Chang, W.H., Lu, H.Y. and Shih, C.C. (2022) Tolvaptan Re-duces Angiotensin II-Induced Experimental Abdominal Aortic Aneurysm and Dissection. Vascular Pharmacology, 144, Article ID: 106973.
https://doi.org/10.1016/j.vph.2022.106973
|
[16]
|
Blair, H.A. (2019) Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. Drugs, 79, 303-313.
https://doi.org/10.1007/s40265-019-1056-1
|
[17]
|
Afkarian, M., Zelnick, L.R., Hall, Y.N., Heagerty, P.J., Tuttle, K., Weiss, N.S., et al. (2016) Clinical Manifestations of Kidney Disease among US Adults with Diabetes, 1988-2014. JAMA, 316, 602-610.
https://doi.org/10.1001/jama.2016.10924
|
[18]
|
Akihisa, T., Manabe, S., Kataoka, H., et al. (2021) Dose-Dependent Effect of Tolvaptan on Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease. Kidney360, 2, 1148-1151.
https://doi.org/10.34067/KID.0007342020
|
[19]
|
Kong, X., Zhang, L., Zhang, L., Chen, N., Gu, Y., Yu, X., et al. (2012) Mineral and Bone Disorder in Chinese Dialysis Patients: A Multicenter Study. BMC Nephrology, 13, Article No. 116. https://doi.org/10.1186/1471-2369-13-116
|
[20]
|
Portillo, M.R. and Rodríguez-Ortiz, M.E. (2017) Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies. Reviews in Endocrine and Meta-bolic Disorders, 18, 79-95.
https://doi.org/10.1007/s11154-017-9421-4
|
[21]
|
Himmelfarb, J. and Tuttle, K.R. (2013) New Therapies for Dia-betic Kidney Disease. The New England Journal of Medicine, 369, 2549-2550. https://doi.org/10.1056/NEJMe1313104
|
[22]
|
Garreta, E., Prado, P., Stanifer, M.L., et al. (2022) A Diabetic Milieu Increases ACE2 Expression and Cellular Susceptibility to SARS-CoV-2 Infections in Human Kidney Organoids and Pa-tient Cells. Cell Metab.
https://doi.org/10.1016/j.cmet.2022.04.009
|
[23]
|
Kanda, H. and Yamawaki, K. (2020) Bardoxolone Methyl: Drug Development for Diabetic Kidney Disease. Clin Exp Nephrol, 24, 857-864. https://doi.org/10.1007/s10157-020-01917-5
|
[24]
|
Vincent, K.M., Alrajhi, A., Lazier, J., Bonin, B., Lawrence, S., Weiler, G., et al. (2022) Expanding the Clinical Spectrum of Autosomal-Recessive Renal Tubular Dysgenesis: Two Sib-lings with Neonatal Survival and Review of the Literature. Molecular Genetics & Genomic Medicine, 10, Article No. e1920. https://doi.org/10.1002/mgg3.1920
|
[25]
|
Vaziri, N.D., Liu, S., Farzaneh, S.H., et al. (2015) Dose-Dependent Deleterious and Salutary Actions of the Nrf2 Inducer dh404 in Chronic Kidney Disease. Free Radical Biology and Medi-cine, 86, 374-381.
https://doi.org/10.1016/j.freeradbiomed.2015.04.022
|
[26]
|
Chade, A.R., Zhu, X., Lavi, R., Krier, J.D., Pislaru, S., Simari, R.D., et al. (2009) Endothelial Progenitor Cells Restore Renal Function in Chronic Experimental Renovascular Disease. Circulation, 119, 547-557.
https://doi.org/10.1161/CIRCULATIONAHA.108.788653
|
[27]
|
Wang, Z. and Sun, D. (2018) Adipose-Derived Mesenchymal Stem Cells: A New Tool for the Treatment of Renal Fibrosis. Stem Cells and Development, 27, 1406-1411. https://doi.org/10.1089/scd.2017.0304
|
[28]
|
Cartón-García, F., Saande, C.J., Meraviglia-Crivelli, D., Aldabe, R. and Pastor, F. (2021) Oligonucleotide-Based Therapies for Renal Diseases. Biomedicines, 9, Article No. 303. https://doi.org/10.3390/biomedicines9030303
|